Is Biogen Inc (BIIB) undervalued? · P/E 21, rev $9.89B
Biogen Inc (BIIB) is a drug manufacturers - general company listed on NASDAQ.
This page asks whether Biogen Inc (BIIB) looks cheap on cached numbers — not a DCF toy and not a buy alert.
Latest reported BIIB revenue for 2025-12-31 was $9.89B. Net income was $1.29B. Revenue was up 2.2% from 2024-12-31 to 2025-12-31. BIIB currently screens at market cap $29.33B and trailing P/E 21.4.
BIIB currently screens at market cap $29.33B and trailing P/E 21.4. Cheap versus history or peers still needs a filing reason; a low multiple can be a value trap.
A new BIIB 10-Q can flip this screen overnight. The SEC page is the source.
Not investment advice. Compare BIIB to the stock page model before you treat a low multiple as a gift.
Not investment advice.